{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:20:15Z","timestamp":1764177615738,"version":"3.46.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017624","name":"Achaogen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019383","name":"Cipla Ltd.","doi-asserted-by":"publisher","award":["R01AI090802"],"award-info":[{"award-number":["R01AI090802"]}],"id":[{"id":"10.13039\/100019383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The results of pharmacometric analyses for aminoglycosides were used to support recommendations for dosing regimens adjusted for renal function and a reassessment of the United States Committee on Antimicrobial Susceptibility Testing susceptibility test interpretive criteria for Enterobacterales and Pseudomonas aeruginosa. Susceptible and susceptible-based on therapeutic drug monitoring breakpoints are recommended for extended-interval amikacin, gentamicin, and tobramycin dosing regimens, thus representing adaptable treatable approaches.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf427","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:55:50Z","timestamp":1763816150000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    : Brief Summary"],"prefix":"10.1093","volume":"12","author":[{"given":"Sujata M","family":"Bhavnani","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P","family":"Hammel","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas J","family":"Onufrak","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-6215","authenticated-orcid":false,"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element , North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element , North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida , Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of California at San Diego, San Diego, California ,","place":["USA"]},{"name":"Rady Children\u2019s Hospital , San Diego, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Andes","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc. , Schenectady, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025112612173987300_ofaf427-B1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/clinids\/24.5.786","article-title":"A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Bailey","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2025112612173987300_ofaf427-B2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025112612173987300_ofaf427-B3","volume-title":"Second supplement, M2\u2013A2-S2. Performance standards for antimicrobial disk susceptibility tests. 2nd ed","author":"National Committee for Clinical Laboratory Standards","year":"1982"},{"key":"2025112612173987300_ofaf427-B4","author":"Bhavnani"},{"key":"2025112612173987300_ofaf427-B5","author":"The United States Committee on Antimicrobial Susceptibility Testing"},{"key":"2025112612173987300_ofaf427-B6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf426","article-title":"Evaluation of aminoglycoside dosing regimens adjusted for renal function and in vitro susceptibility test interpretive criteria for Enterobacterales and Pseudomonas aeruginosa","author":"Bhavnani","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025112612173987300_ofaf427-B7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF00542215","article-title":"Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients","volume":"24","author":"Bauer","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"2025112612173987300_ofaf427-B8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003088-200038050-00003","article-title":"Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics","volume":"38","author":"Bearden","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2025112612173987300_ofaf427-B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-3323-5_9","volume-title":"Antibiotic pharmacodynamics","author":"Bowers","year":"2016"},{"key":"2025112612173987300_ofaf427-B10","author":"Sargent Pharmaceuticals, Inc"},{"key":"2025112612173987300_ofaf427-B11","author":"Hospira, Inc. Gentamicin sulfate [package Insert]. 2024. Lake Forest, IL"},{"key":"2025112612173987300_ofaf427-B12","author":"Hospira, Inc. Tobramycin sulfate injection, solution [package insert]. 2024. Lake Forest, IL"},{"key":"2025112612173987300_ofaf427-B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coph.2017.09.009","article-title":"Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection","volume":"36","author":"Trang","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"2025112612173987300_ofaf427-B14","doi-asserted-by":"crossref","first-page":"e0213021","DOI":"10.1128\/aac.02130-21","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses as support for meropenem-vaborbactam dosing regimens and susceptibility breakpoints","volume":"66","author":"Bhavnani","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112612173987300_ofaf427-B15","author":"Food and Drug Administration Drug Approval Package"},{"key":"2025112612173987300_ofaf427-B16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025112612173987300_ofaf427-B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025112612173987300_ofaf427-B18","author":"Antimicrobial Therapy, Inc"},{"key":"2025112612173987300_ofaf427-B19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27 Suppl C","author":"Craig","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2025112612173987300_ofaf427-B20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1445-5994.1995.tb01529.x","article-title":"Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve","volume":"25","author":"Barclay","year":"1995","journal-title":"Aust N Z J Med"},{"key":"2025112612173987300_ofaf427-B21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112612173987300_ofaf427-B22","volume-title":"M100-S35. Performance standards for antimicrobial susceptibility testing: 35th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2025"},{"key":"2025112612173987300_ofaf427-B23","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025112612173987300_ofaf427-B24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025112612173987300_ofaf427-B25","author":"Food and Drug Administration"},{"key":"2025112612173987300_ofaf427-B26","author":"The European Committee on antimicrobial Susceptibility Testing"},{"key":"2025112612173987300_ofaf427-B27","volume-title":"Aminoglycoside breakpoints for Enterobacterales and Pseudomonas aeruginosa: rational document","author":"Clinical and Laboratory Standards Institute. MR16","year":"2025","edition":"1st ed"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf427\/65551551\/ofaf427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf427\/65551551\/ofaf427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:17:51Z","timestamp":1764177471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf427\/8343496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf427","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,26]]},"article-number":"ofaf427"}}